The novel respiratory disease COVID-19 produces varying symptoms, with fever, cough, and shortness of breath being common. In older adults, we found that preexisting dementia is a major risk factor (odds ratio \[OR\] = 3.07, 95% CI: 1.71 to 5.50) for COVID-19 severity in the UK Biobank (UKB) ([@CIT0001]). In another UK study of 16,749 patients hospitalized for COVID-19 ([@CIT0002]), dementia was among the common comorbidities and was associated with higher mortality. Additionally, impaired consciousness, including delirium, is common in severe cases ([@CIT0003]). The *ApoE* e4 genotype is associated with both dementia and delirium ([@CIT0004]), with the e4e4 (homozygous) genotype associated with a 14-fold increase in risk of Alzheimer's disease ([@CIT0005]) compared to the common e3e3 genotype, in populations with European ancestries. We, therefore, aimed to test associations between *ApoE* e4 alleles and COVID-19 severity, using the UKB data.

UKB is a community cohort currently aged 48 to 86 ([@CIT0006]). COVID-19 laboratory test results for UKB participants in England are available from March 16 to April 26, 2020, the peak period of COVID-19 incidence in the current outbreak. During this period, COVID-19 testing was largely restricted to hospital inpatients with clinical signs of infection, and therefore test positivity is a marker of severe COVID-19 infection ([@CIT0007]).

We analyzed UKB data from genetically European ancestry participants ([@CIT0008]) (*n* = 451,367, 90% of sample) attending baseline assessment centers in England (*n* = 398,073), excluding participants who died before the epidemic (*n* = 15,885). Single nucleotide polymorphism (SNP) data for rs429358 and rs7412 was used to determine *ApoE* genotypes: *ApoE* e4e4 homozygotes (*n* = 9,022, 3%), e3e4 (*n* = 90,469, 28%), and e3e3 (most common genotype, *n* = 223,457, 69%) genotype groups (final *n* = 322,948). Mean age was 68 years (*SD* = 8) with 176,951 females (55%). There were 622 positive COVID-19 patients ([Table 1](#T1){ref-type="table"}) including 37 with e4e4 (positivity rate: 410/100,000) and 401 with e3e3 (179 per 100,000). A logistic regression model was used to compare e3e4 or e4e4 genotypes to e3e3 for COVID-19 positivity status, adjusted for: sex; age at the COVID-19 test or age on April 26, 2020 (the last test date); baseline UKB assessment center in England; genotyping array type; and the top five genetic principal components (accounting for possible population admixture).

###### 

Risk of Severe COVID-19, Comparing Participants With *ApoE* e3e4 or e4e4 to e3e3 Genotypes in UK Biobank

                                      *n*       Negative or not Tested   Positive   Positivity Rate per 100,000   OR (95% CI)^a^      *p*-value
  ----------------------------------- --------- ------------------------ ---------- ----------------------------- ------------------- -----------
  All                                                                                                                                 
   e3e3                               223,457   223,056                  401        179                           \-                  \-
   e3e4                               90,469    90,285                   184        203                           1.14 (0.95, 1.35)   .15
   e4e4                               9,022     8,985                    37         410                           2.31 (1.65, 3.24)   1.19E-06
  Excluding dementia                                                                                                                  
   e3e3                               222,968   222,574                  394        177                           \-                  \-
   e3e4                               90,013    89,840                   173        192                           1.09 (0.91, 1.31)   .338
   e4e4                               8,877     8,840                    37         417                           2.39 (1.71, 3.35)   4.26E-07
  Excluding hypertension                                                                                                              
   e3e3                               151,018   150,792                  226        150                           \-                  \-
   e3e4                               61,249    61,157                   92         150                           1.00 (0.79, 1.28)   .981
   e4e4                               6,120     6,098                    22         359                           2.41 (1.56, 3.74)   8.21E-05
  Excluding coronary artery disease                                                                                                   
   e3e3                               204,017   203,684                  333        163                           \-                  \-
   e3e4                               82,099    81,948                   151        184                           1.13 (0.93, 1.37)   0.207
   e4e4                               8,164     8,132                    32         392                           2.43 (1.69, 3.50)   1.65E-06
  Excluding type 2 diabetes                                                                                                           
   e3e3                               211,482   211,136                  346        164                           \-                  \-
   e3e4                               85,983    85,827                   156        181                           1.11 (0.92, 1.34)   .275
   e4e4                               8,616     8,581                    35         406                           2.51 (1.77, 3.55)   2.42E-07

*Note*: ^a^Adjusted for sex, age at the COVID-19 test or age on April 26, 2020 (the last test date), assessment center in England, genotyping array type, and the top five genetic principal components.

*ApoE* e4e4 homozygotes were more likely to be COVID-19 test positives (OR = 2.31, 95% CI: 1.65 to 3.24, *p* = 1.19 × 10^--6^) compared to e3e3 homozygotes ([Table 1](#T1){ref-type="table"}). The association was similar after removing participants with *ApoE* e4 associated diseases that were also linked to COVID-19 severity: participants without dementia (OR = 2.39, 95% CI: 1.71 to 3.35); hypertension (OR = 2.41, 95% CI: 1.56 to 3.74); coronary artery disease (myocardial infarction or angina) (OR = 2.43, 95% CI: 1.69 to 3.50) or type 2 diabetes (OR = 2.51, 95% CI: 1.77 to 3.55) ([Table 1](#T1){ref-type="table"}), based on preexisting diagnoses from baseline self-reports or hospital discharge statistics (updated to March 2017). The estimates were little changed using 136,146 participants with additional general practice data (up to 2017): participants without dementia (OR = 2.53, 95% CI: 1.46 to 4.39); hypertension (OR = 2.67, 95% CI: 1.34 to 5.32); coronary artery disease (OR = 2.86, 95% CI: 1.65 to 4.98) or type 2 diabetes (OR = 2.73, 95% CI: 1.57 to 4.76). The results were also similar after excluding 51,430 participants related to the third degree or closer (OR = 2.34, 95% CI: 1.62 to 3.38). Of 622 included participants who tested positive for COVID-19, 417 (67%) were noted to the laboratory to be inpatients when the sample was taken: unfortunately, data on later admission to hospital is not available ([@CIT0007]). Including only those known to have been inpatients when tested made little difference to the excess risk associated with *ApoE* e4e4 status (OR = 2.32, 95% CI: 1.54 to 3.29), compared to OR = 2.31 (95% CI: 1.65 to 3.24) using all the tested samples.

In conclusion, the *ApoE* e4e4 allele increases risks of severe COVID-19 infection, independent of preexisting dementia, cardiovascular disease, and type-2 diabetes. *ApoE* e4 not only affects lipoprotein function (and subsequent cardio-metabolic diseases) but also moderates macrophage pro-/anti-inflammatory phenotypes ([@CIT0009]). The novel coronavirus SARS-CoV-2 causing COVID-19 uses the ACE2 receptor for cell entry. ACE2 is highly expressed in type II alveolar cells in the lungs, where *ApoE* is one of the highly co-expressed genes ([@CIT0010]). Further investigation is needed to understand the biological mechanisms linking *ApoE* genotypes to COVID-19 severity.
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